Loading company…
SynRx Therapeutics develops oncology drugs targeting DNA damage repair pathways.
Founded in 2021 and based in Hangzhou, SynRx Therapeutics develops small molecule oncology drugs targeting DNA damage repair mechanisms. Its pipeline includes preclinical and clinical programs for solid tumors and other cancers. The company has operations in Shanghai and was founded by Professor Yu Xiaochun. In December 2025, it closed a Series A round led by ZJ Biomedicine and High-end Equipment Industry Fund to advance clinical development and its research platform.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in